Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4663
Abstract: Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor… read more here.
Keywords: cell; alk rearranged; cell free; next generation ... See more keywords
Cytological features in eight patients with ALK‐rearranged lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23879
Abstract: ALK‐rearranged lung cancer has been recently identified. Although signet‐ring cell morphology and mucinous cribriform pattern are considered to be characteristic of ALK‐rearranged lung cancer. Some studies have also suggested cytological features. read more here.
Keywords: alk rearranged; rearranged lung; cytological features; lung cancer ... See more keywords
ALK‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23097
Abstract: Anaplastic lymphoma kinase (ALK) fusions are oncogenic drivers in diverse cancer types. Although well established in inflammatory myofibroblastic tumor (IMT) and epithelioid fibrous histiocytoma (EFH), ALK rearrangements also occur in the emerging family of kinase… read more here.
Keywords: rearranged mesenchymal; mesenchymal neoplasms; alk rearranged; fusion positive ... See more keywords
Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors
Sign Up to like & getrecommendations! Published in 2018 at "Virchows Archiv"
DOI: 10.1007/s00428-018-2428-8
Abstract: We examined the value of targeted molecular screening for the identification of uterine anaplastic lymphoma kinase (ALK)-rearranged mesenchymal tumors, including ALK immunohistochemistry followed by molecular genetic testing, in all uterine leiomyosarcomas and STUMPs (smooth muscle… read more here.
Keywords: rearranged mesenchymal; alk; mesenchymal tumors; uterine leiomyosarcomas ... See more keywords
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00989-6
Abstract: Purpose of Review Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK… read more here.
Keywords: non small; alk; cell lung; lung cancer ... See more keywords
Lorlatinib in ALK-Rearranged Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer cell"
DOI: 10.1016/j.ccell.2020.12.017
Abstract: Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with… read more here.
Keywords: lorlatinib alk; lung cancer; cancer; alk rearranged ... See more keywords
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2021.102178
Abstract: Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains of ROS1 and ALK defines… read more here.
Keywords: treatment; ros1 alk; non small; cancer ... See more keywords
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Nature Medicine"
DOI: 10.1038/nm.4497
Abstract: Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors, approximately half harbor resistance mutations… read more here.
Keywords: alk inhibitors; alk; rearranged non; inhibition ... See more keywords
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy333
Abstract: Abstract Background We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). Patients and methods ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in… read more here.
Keywords: versus months; months versus; treatment; alk rearranged ... See more keywords
Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset
Sign Up to like & getrecommendations! Published in 2017 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx045
Abstract: Introduction Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset… read more here.
Keywords: lymphoma kinase; rearranged non; kinase; anaplastic lymphoma ... See more keywords
ALK‐rearranged squamous cell carcinoma of the lung
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13818
Abstract: ALK rearrangement is a very rare subset of squamous cell carcinoma (SCC) and one of the clinical features in patients is lack of data. Here, we report eight patients diagnosed with SCC of the lung… read more here.
Keywords: alk rearranged; cell carcinoma; squamous cell; lung ... See more keywords